Herpes simplex encephalitis: virologic and serologic study of a patient treated with an interferon inducer.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to R W Chambers.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
High-titered yields of human cytomegalovirus (CMV), strain AD 169, were produced in WI-38 cells in large roller bottles. Maximum plaque titers were observed by the 4th day after infection at which time infectivity in the medium was 200 times greater than that associated with the cells. Virus released into the medium was recovered by sedimentation in a sucrose gradient in a continuous-flow centrifuge rotor. Maximal viral infectivity was found at a sucrose concentration of 42%, equivalent to a density of 1.18 g/cm(3). Deoxyribonucleic acid extracted from these preparations was about 80% viral and 20% cellular as judged by equilibrium centrifugation in cesium chloride density gradients.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
This report describes experiments showing that tRNA(Ala) (II) can be cleaved specifically at the G residue of its anticodon to give "half" molecules in high yield. Neither of these fragments has alanine-acceptor activity, but this activity can be reconstituted by mixing the fragments in the presence of Mg(+2). In dilute salt, on the other hand, the active complex dissociates spontaneously at 25 degrees into the two fragments. Thus, both "halves" of tRNA(Ala) (II) are necessary for acceptor activity and, in the presence of Mg(+2), combination of these fragments to give an active duplex is thermodynamically favorable.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The initial phase of a computerized on-line donor processing system was developed and demonstrated at the American National Red Cross, Washington Regional Donor Center and at bloodmobile operations. It was used for entry of donor registration information and for screening donors early in the donation procedure against a list of deferred donors. This demonstration took place with the computerized donor processing system running in parallel with the present manual operations. Since volunteer staff usually assist in the operation of most blood collection facilities, it was necessary to demonstrate that nontechnical personnel could operate the computerized system.
Clerical and administrative errors are the most common mistakes in blood banking, with errors of sample or patient identification accounting for the majority of mistakes. In an effort to reduce the incidence of human errors, three automated donor-recipient identification systems were developed and were evaluated under clinical conditions. After two years of development and bench testing, each set of equipment was tested, along with established procedures, at a large clinical center, a medium-sized community hospital and a regional donor center. Although none of the systems, as tested, proved acceptable under clinical conditions, a great deal was learned about prototype equipment testing in the clinical setting. Future development of identification systems for clinical use should respond to carefully defined problems, apply in all areas of the hospital or donor center, and be convenient and reliable. The development of the equipment should involve established manufacturers and be subject to exacting preclinical testing.